This suggests that passive immunization with tau antibodies is actually a practical therapeutic focus on and that the CSF amount of p-tau262/356 or of the microtubule binding area (MTBD) can serve as a valuable biomarker of tau pathology to observe tau therapeutics in clinical trials.Immerse on your own in TAU’s Daring and emotionally charged wil